Il-Yang Pharm
As of the edition of 20 October 2026, Il-Yang Pharm runs 3 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Radotinib | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Cancer: 5 trials led
- Blood and lymph: 4 trials led
- Digestive system: 4 trials led